- Small trials are ongoing for cell therapies to modulate the immune system.

- AntiCD40 monoclonal antibody (CFZ533) has the potential to block the co-stimulatory CD40â€“CD154 pathway and is a possible upcoming clinical treatment for acute rejection.

- There are a few clinical trials underway for checking the safety and efficacy of immunomodulatory medicines for desensitization and antibody medicated rejections.